A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )

NCT05176639 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: VRDN-001 Phase 3 Cohort (THRIVE)
DRUG: VRDN-001 Placebo

Sponsor

Viridian Therapeutics, Inc.